Dexamethasone Intravitreal Implant (Ozurdex)

Ozurdex (dexamethasone 0.19 mg intravitreal implant) is covered for FDA‑approved indications — macular edema after branch or central retinal vein occlusion, non‑infectious posterior segment uveitis, and diabetic macular edema — and is excluded in patients with ocular/periocular infection, glaucoma with cup‑to‑disc ratio >0.8, or a torn/ruptured posterior lens capsule. Coverage requires documentation of the diagnosis, clinical records supporting the 0.19 mg dose and treatment plan, verification of absence of the listed contraindications, and authorization lasts 12 months.

"The treatment of macular edema following branch retinal vein occlusion or central retinal vein occlusion."

Sign up to see full coverage criteria, indications, and limitations.